<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00407966</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02986</org_study_id>
    <secondary_id>NCI-2012-02986</secondary_id>
    <secondary_id>U01CA070095</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>J0669</secondary_id>
    <secondary_id>7845</secondary_id>
    <nct_id>NCT00407966</nct_id>
  </id_info>
  <brief_title>Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
  <official_title>Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying the side effects and how well giving alvocidib together with
      cytarabine and mitoxantrone works in treating patients with newly diagnosed acute myeloid
      leukemia. Drugs used in chemotherapy, such as alvocidib, cytarabine, and mitoxantrone, work
      in different ways to stop the growth of cancer cells, either by killing the cells or by
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill
      more cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the efficacy and toxicities of flavopiridol (alvocidib) followed by ara-C and
      mitoxantrone in adults with newly diagnosed acute myelogenous leukemia (AML) with poor-risk
      features.

      II. To determine the disease free and overall survival of patients exhibiting a response to
      treatment with flavopiridol followed by ara-C and mitoxantrone.

      OUTLINE:

      Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72
      hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Beginning 35-63
      days after completion of course 1, patients achieving complete or partial remission may
      receive a second course of treatment as above.

      Patients age 50 and over with &quot;core binding factor&quot; acute myeloid leukemia (AML) (e.g.,
      t[8;21], inv[16], or t[16;16]) achieving a complete remission after course 1 of treatment may
      receive 3-4 courses of consolidation therapy comprising high-dose cytarabine at the
      discretion of the investigator.

      After completion of study treatment, patients are followed periodically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response</measure>
    <time_frame>6 months</time_frame>
    <description>Bone marrow showing less than 5% myeloblasts with normal maturation of all cell lines, an Absolute Neutrophil Count of at least 1000/mililiter and a platelet count of 100,000 mililiter, absence of blast in peripheral blood, absence of identifiable leukemic cells in the bone marrow, clearance of disease-associated cytogenetic abnormalities, and clearance of any previously existing extramedullary disease. A complete remission must be confirmed 4 to 6 weeks after the initial documentation. If possible, at least one bone marrow biopsy should be performed to confirm the complete remission.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Adult Acute Basophilic Leukemia</condition>
  <condition>Adult Acute Eosinophilic Leukemia</condition>
  <condition>Adult Acute Megakaryoblastic Leukemia (M7)</condition>
  <condition>Adult Acute Minimally Differentiated Myeloid Leukemia (M0)</condition>
  <condition>Adult Acute Monoblastic Leukemia (M5a)</condition>
  <condition>Adult Acute Monocytic Leukemia (M5b)</condition>
  <condition>Adult Acute Myeloblastic Leukemia With Maturation (M2)</condition>
  <condition>Adult Acute Myeloblastic Leukemia Without Maturation (M1)</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Acute Myelomonocytic Leukemia (M4)</condition>
  <condition>Adult Erythroleukemia (M6a)</condition>
  <condition>Adult Pure Erythroid Leukemia (M6b)</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (alvocidib, cytarabine, mitoxantrone hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Beginning 35-63 days after completion of course 1, patients achieving complete or partial remission may receive a second course of treatment as above.
Patients age 50 and over with &quot;core binding factor&quot; acute myeloid leukemia (AML) (e.g., t[8;21], inv[16], or t[16;16]) achieving a complete remission after course 1 of treatment may receive 3-4 courses of consolidation therapy comprising high-dose cytarabine at the discretion of the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (alvocidib, cytarabine, mitoxantrone hydrochloride)</arm_group_label>
    <other_name>FLAVO</other_name>
    <other_name>flavopiridol</other_name>
    <other_name>HMR 1275</other_name>
    <other_name>L-868275</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (alvocidib, cytarabine, mitoxantrone hydrochloride)</arm_group_label>
    <other_name>ARA-C</other_name>
    <other_name>arabinofuranosylcytosine</other_name>
    <other_name>arabinosylcytosine</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (alvocidib, cytarabine, mitoxantrone hydrochloride)</arm_group_label>
    <other_name>CL 232315</other_name>
    <other_name>DHAD</other_name>
    <other_name>DHAQ</other_name>
    <other_name>Novantrone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with established, pathologically confirmed diagnoses of newly diagnosed,
             poor-risk Acute Myeloid Leukemia(AML) including de novo and secondary Acute Myeloid
             Leukemias but excluding newly diagnosed acute progranulocytic leukemia (APL, M3) will
             be considered eligible for study

          -  ECOG performance status 0-2

          -  Patient must be able to give informed consent

          -  Serum creatinine =&lt; 2.0

          -  ALT, AST =&lt; 5 x upper limit of normal

          -  Bilirubin =&lt; 2.0 mg/dl

          -  Left ventricular ejection fraction &gt;= 45%

          -  Newly diagnosed AML, subtypes M0,1,2,4-7 but excluding M3 (APL) with poor-risk
             features, including:

               -  Age &gt; 50 years, or age &gt; 18 years with one or more of the following criteria:

                    -  Antecedent hematologic disorder including myelodysplasia (MDS)-related AML
                       (MDS/AML) and prior myeloproliferative disorder (MPD)

                    -  Treatment-related AML

                    -  AML with trilineage dysplasia (AML-TLD)

                    -  Adverse cytogenetics (defined as -5/-5q; -7/-7q; abnormal 3q, 9q, 11q, 20q,
                       21q or 17p; t(6;9); t(9;22); trisomy 8; trisomy 13, complex karyotypes (&gt;= 3
                       unrelated abnormalities)

        Exclusion Criteria:

          -  Patients who have received hydroxyurea alone or have received non-cytotoxic therapies
             previously for MDS or MPD (e.g., thalidomide or lenalidomide, interferon, cytokines,
             low-dose 5-azacytidine, low-dose cytoxan) will be eligible for this trial

          -  Any previous treatment with flavopiridol

          -  Concomitant chemotherapy, radiation therapy, or immunotherapy

          -  Hyperleukocytosis with &gt;= 50,000 blasts/uL; leukapheresis or hydroxyurea may be used
             immediately prior to study drug administration for cytoreduction; must be stopped 24
             hours before first dose of Flavopiridol

          -  Acute Progranulocytic Leukemia (APL, M3)

          -  Active CNS leukemia

          -  Active, uncontrolled infection; patients with infection under active treatment and
             controlled with antibiotics are eligible

          -  Presence of other life-threatening illness

          -  Patients with mental deficits and/or psychiatric history that preclude them form
             giving informed consent or from following protocol

          -  Pregnant and nursing patients are excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Karp</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University/Sidney Kimmel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2006</study_first_submitted>
  <study_first_submitted_qc>December 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2006</study_first_posted>
  <results_first_submitted>May 1, 2012</results_first_submitted>
  <results_first_submitted_qc>January 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2013</results_first_posted>
  <last_update_submitted>July 14, 2015</last_update_submitted>
  <last_update_submitted_qc>July 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Basophilic, Acute</mesh_term>
    <mesh_term>Leukemia, Eosinophilic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From December 2006 through June 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A</title>
          <description>Flavopiridol, ara-C, mitoxantrone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>CR</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A</title>
          <description>Flavopiridol, ara-C, mitoxantrone</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Response</title>
        <description>Bone marrow showing less than 5% myeloblasts with normal maturation of all cell lines, an Absolute Neutrophil Count of at least 1000/mililiter and a platelet count of 100,000 mililiter, absence of blast in peripheral blood, absence of identifiable leukemic cells in the bone marrow, clearance of disease-associated cytogenetic abnormalities, and clearance of any previously existing extramedullary disease. A complete remission must be confirmed 4 to 6 weeks after the initial documentation. If possible, at least one bone marrow biopsy should be performed to confirm the complete remission.</description>
        <time_frame>6 months</time_frame>
        <population>Total number of participants entered between December 2006 and June 2008</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Flavopiridol, ara-C, mitoxantrone</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response</title>
          <description>Bone marrow showing less than 5% myeloblasts with normal maturation of all cell lines, an Absolute Neutrophil Count of at least 1000/mililiter and a platelet count of 100,000 mililiter, absence of blast in peripheral blood, absence of identifiable leukemic cells in the bone marrow, clearance of disease-associated cytogenetic abnormalities, and clearance of any previously existing extramedullary disease. A complete remission must be confirmed 4 to 6 weeks after the initial documentation. If possible, at least one bone marrow biopsy should be performed to confirm the complete remission.</description>
          <population>Total number of participants entered between December 2006 and June 2008</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of treatmetn through recovery of blood counts and response assessment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A</title>
          <description>Flavopiridol, ara-C, mitoxantrone</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac dysfunction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Desseminated Intravascular Coagulopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>oral mucositis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>GI Mucositis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Judith Karp, MD</name_or_title>
      <organization>SKCCC</organization>
      <phone>410-502-7726</phone>
      <email>jkarp2@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

